1. Brown, JWL, Coles, A, Horakova, D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187, https://pubmed.ncbi.nlm.nih.gov/30644981/ (accessed 29 June 2021).
Google Scholar2. Mahad, DH, Trapp, BD, Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2): 183–193, https://pubmed.ncbi.nlm.nih.gov/25772897/ (accessed 28 June 2021).
Google Scholar | Crossref3. Lublin, FD, Reingold, SC, Cohen, JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366/ (accessed 28 June 2021).
Google Scholar4. Hawker, K, O’Connor, P, Freedman, MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460–471, https://pubmed.ncbi.nlm.nih.gov/19847908/ (accessed 28 June 2021).
Google Scholar | Crossref5. Montalban, X, Hauser, SL, Kappos, L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209–220.
Google Scholar | Crossref | Medline | ISI6. Wolinsky, JS, Arnold, D, Bar-Or, A, et al. Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial. Mult Scler J 2016; 22(1_suppl): 2–84, https://journals.sagepub.com/doi/full/10.1177/1352458516631279 (accessed 28 June 2021).
Google Scholar7. Weideman, AM, Tapia-Maltos, MA, Johnson, K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 2017; 8: 577, www.frontiersin.org (accessed 29 June 2021).
Google Scholar | Crossref8. Lorscheider, J, Kuhle, J, Izquierdo, G, et al. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: A cohort study. Eur J Neurol 2019; 26(2): 363–370, https://onlinelibrary.wiley.com/doi/full/10.1111/ene.13824 (accessed 28 June 2021).
Google Scholar9. Kalincik, T, Lizak, N, Malpas, CB, et al. Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. JAMA Neurol 2020; 77(11): 1398–1407, https://jamanetwork.com/ (accessed 28 June 2021).
Google Scholar | Crossref10. Feinstein, A, Freeman, J, Lo, AC. Treatment of progressive multiple sclerosis: What works, what does not, and what is needed. Lancet Neurol 2015; 14(2): 194–207, https://pubmed.ncbi.nlm.nih.gov/25772898/ (accessed 28 June 2021).
Google Scholar | Crossref